BlackRock Fund Advisors’s Akebia Therapeutics AKBA Stock Holding History

BlackRock Fund Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$17.7M	Buy	1,703,987 +196,749	+13%	+$1.69M	﹤0.01%	2252
2016 Q3	$13.6M	Buy	1,507,238 +98,740	+7%	+$839K	﹤0.01%	2279
2016 Q2	$10.5M	Buy	1,408,498 +107,049	+8%	+$934K	﹤0.01%	2383
2016 Q1	$11.7M	Buy	1,301,449 +275,914	+27%	+$2.24M	﹤0.01%	2273
2015 Q4	$13.3M	Buy	1,025,535 +4,391	+0.4%	+$44.8K	﹤0.01%	2288
2015 Q3	$9.86M	Buy	1,021,144 +31,621	+3%	+$290K	﹤0.01%	2376
2015 Q2	$10.2M	Buy	989,523 +515,500	+109%	+$4.4M	﹤0.01%	2486
2015 Q1	$5.27M	Buy	474,023 +16,739	+4%	+$178K	﹤0.01%	2817
2014 Q4	$5.32M	Buy	457,284 +268,909	+143%	+$3.86M	﹤0.01%	2841
2014 Q3	$4.17M	Sell	188,375 -4,442	-2%	-$102K	﹤0.01%	2857
2014 Q2	$5.36M	Buy	+192,817	New	+$4.64M	﹤0.01%	2793

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock Fund Advisors's AKBA Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Akebia Therapeutics (AKBA) stake by 13% in Q4 2016, buying an estimated $1.69M and bringing the position to 1,703,987 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

BlackRock Fund Advisors first reported a position in AKBA in Q2 2014 and has held it in 11 quarters since. 94 funds tracked by Wall St. Rank hold AKBA as of Q4 2016.

BlackRock Fund Advisors held 1,703,987 shares of Akebia Therapeutics worth $17.7M as of Q4 2016.
BlackRock Fund Advisors bought 196,749 Akebia Therapeutics shares in Q4 2016, an estimated $1.69M.
Akebia Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2252 holding.
BlackRock Fund Advisors first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 11 quarters since.
94 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.